Bristol Myers Squibb Cash on Hand 2010-2022 | BMY

Bristol Myers Squibb cash on hand from 2010 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Bristol Myers Squibb cash on hand for the quarter ending March 31, 2022 was $14.968B, a 15.76% increase year-over-year.
  • Bristol Myers Squibb cash on hand for 2021 was $16.966B, a 7.17% increase from 2020.
  • Bristol Myers Squibb cash on hand for 2020 was $15.831B, a 2.85% increase from 2019.
  • Bristol Myers Squibb cash on hand for 2019 was $15.393B, a 75.74% increase from 2018.
Bristol Myers Squibb Annual Cash on Hand
(Millions of US $)
2021 $16,966
2020 $15,831
2019 $15,393
2018 $8,759
2017 $6,812
2016 $6,350
2015 $4,270
2014 $7,435
2013 $4,525
2012 $2,829
2011 $8,733
2010 $7,301
2009 $8,514
Bristol Myers Squibb Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $14,968
2021-12-31 $16,966
2021-09-30 $15,663
2021-06-30 $12,970
2021-03-31 $12,930
2020-12-31 $15,831
2020-09-30 $21,155
2020-06-30 $21,658
2020-03-31 $18,322
2019-12-31 $15,393
2019-09-30 $32,542
2019-06-30 $29,357
2019-03-31 $8,764
2018-12-31 $8,759
2018-09-30 $6,830
2018-06-30 $6,075
2018-03-31 $6,770
2017-12-31 $6,812
2017-09-30 $7,122
2017-06-30 $6,505
2017-03-31 $6,109
2016-12-31 $6,350
2016-09-30 $5,560
2016-06-30 $4,651
2016-03-31 $4,307
2015-12-31 $4,270
2015-09-30 $5,413
2015-06-30 $5,476
2015-03-31 $7,607
2014-12-31 $7,435
2014-09-30 $7,221
2014-06-30 $7,175
2014-03-31 $7,059
2013-12-31 $4,525
2013-09-30 $2,722
2013-06-30 $2,799
2013-03-31 $2,533
2012-12-31 $2,829
2012-09-30 $2,930
2012-06-30 $5,037
2012-03-31 $5,029
2011-12-31 $8,733
2011-09-30 $8,193
2011-06-30 $7,670
2011-03-31 $6,793
2010-12-31 $7,301
2010-09-30 $8,359
2010-06-30 $7,454
2010-03-31 $6,776
2009-12-31 $8,514
2009-09-30 $6,669
2009-06-30 $8,120
2009-03-31 $8,920
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $163.597B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00